Proteomedix and New Horizon Health Limited enter into a research and development partnership
Schlieren-Zurich, Switzerland, September 21, 2021. Proteomedix, the Swiss cancer diagnostics company has entered into a research and development partnership with New Horizon Health Limited (6606.SEHK). To support the joint program New Horizon Health has invested CHF 3.0 million in a convertible loan in Proteomedix. The partnership builds on complimentary platform and biomarker developments with utility in cancer patient management.
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the European market early 2020. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.
About New Horizon Health
Founded in 2015, New Horizon Health is the pioneer and market leader in China’s cancer screening sector focusing on early detection of high-incidence cancers at home. It aims to promote innovation in cancer screening technology and expedite the widespread take-up of cancer screening technology in China. On 18 February, 2021, New Horizon Health was successfully listed on the Stock Exchange of Hong Kong under the stock code of 6606.HK, becoming the “first cancer screening stock in China”.